Counter-point. Routine use of perioperative intravesical chemotherapy after TURBT: against.

摘要

Before asserting the case against its routine use, let there be no doubt that perioperative instillation of chemotherapy (PI) after transurethral resection of bladder tumor (TURBT) decreases tumor recurrence rates, and we discuss its potential role with all patients presenting with new apparent low-grade bladder cancers. According to the largest dataset-1476 patients from 7 studies considered in a meta-analysis by Sylvester et al-recurrences were reduced by 11.7% overall, from a rate of 48.4% after transurethral resection (TUR) alone to 36.7% after the addition of a single postoperative dose of intravesical chemotherapy.